News

Phase 1 study of CS014 in healthy volunteers moves to last part

A Phase 1 clinical trial testing Cereno Scientific’s candidate therapy for idiopathic pulmonary fibrosis (IPF) in healthy volunteers has moved to its final part, the company has announced. This first-in-human, open-label trial is testing CS014 at single and multiple ascending doses in about 48 participants. The part that evaluated…

Runx2 protein may be treatment target for pulmonary fibrosis

A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows, suggesting that inhibiting this protein may be an effective strategy for treating the disease. “Our study suggests Runx2 is a potential therapeutic target for preventing or treating pulmonary…

Nerandomilast shows promise for progressive pulmonary fibrosis

Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with progressive pulmonary fibrosis in a Phase 3 study, according to top-line data announced by the company. With those results, nerandomilast met the primary endpoint, or goal, of the study,…

Enzyme responsible for fatty acid may be IPF therapeutic target

Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition. Experiments showed that FASN was elevated in lung scar…